Romurtide
Also known as: MDP-Lys(L18), Murametide (related compound), Muroctasin, Romurtide, Thymopoietin analog
Source Romurtide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Romurtide is a synthetic peptide investigated for its ability to accelerate recovery of neutrophils after chemotherapy or bone‑marrow suppression. It is not approved by major regulatory agencies outside Japan.
Mechanism of Action
Stimulates production of colony‑stimulating factors and promotes proliferation of granulocyte‑macrophage progenitors; may activate NOD2 signaling in macrophages
Routes of Administration
Goals & Uses
- ImmunostimulationImmunomodulationModerate
- Platelet recoveryHematopoietic SupportModerate
- Hematopoietic recovery after radiotherapyHematopoietic SupportModerate
- Neutropenia recoveryHematologyModerate
- Treatment of chemotherapy-induced leukopeniaHematopoietic SupportHigh
Contraindications
- Known hypersensitivity to Romurtide or excipientsAllergyHigh
- Severe hepatic or renal impairmentOrgan ImpairmentModerate
- Hypersensitivity to romurtide or MDP analoguesAllergyHigh
- Autoimmune disordersImmuneModerate
Adverse Effects
- Fever / PyrexiaSystemicCommon
- Hypersensitivity reactionsImmunologicRare
- Injection site reactionsLocalCommon
- Malaise / fatigueSystemicUncommon
- Chills / rigorsSystemicCommon
- FeverSystemicUncommonElevated body temperature
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Cytotoxic chemotherapy agentsLow
- Immunosuppressants (e.g., corticosteroids)Moderate
- Concurrent myelosuppressive chemotherapyModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pediatric patients (<12 y)AgeRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization in the European Union.
- United StatesUnapprovedInvestigational; not FDA‑approved.
- United KingdomUnapprovedNot authorized for clinical use.
Approved in Japan for clinical use to treat leukopenia induced by chemotherapy or radiotherapy. Not approved by the US FDA or EMA. Limited regulatory recognition outside Japan.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Romurtide?
Romurtide is a synthetic peptide investigated for its ability to accelerate recovery of neutrophils after chemotherapy or bone‑marrow suppression. It is not approved by major regulatory agencies outside Japan.
What is Romurtide used for?
Romurtide is educationally associated with: Immunostimulation, Platelet recovery, Hematopoietic recovery after radiotherapy, Neutropenia recovery, Treatment of chemotherapy-induced leukopenia. Educational only — not medical advice.
How is Romurtide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Romurtide?
Reported adverse effects include: Fever / Pyrexia, Hypersensitivity reactions, Injection site reactions, Malaise / fatigue, Chills / rigors, Fever, Elevated liver enzymes, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Romurtide?
Recorded contraindications: Known hypersensitivity to Romurtide or excipients, Severe hepatic or renal impairment, Hypersensitivity to romurtide or MDP analogues, Autoimmune disorders. Consult a qualified clinician before use.